# Severe Hypertriglyceridemia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/severe-hypertriglyceridemia

> 6 upcoming FDA catalysts in severe Hypertriglyceridemia: TRYNGOLZA (olezarsen, IONS) on March 2027 (primary completion); TRYNGOLZA (olezarsen, IONS) on Mar to Jun 2027 (topline data readout); solbinsiran (LLY) on March 2027 (primary completion); solbinsiran (LLY) on Mar to Jun 2027 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 12, 2026 | [REDEMPLO (plozasiran) primary completion](https://sec-api.dev/pdufa/plozasiran) | ARWR | Severe Hypertriglyceridemia | completed | "NCT06347003 (Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-12 (ACTUAL); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06347003)) |
| June 17, 2026 | [REDEMPLO (plozasiran) primary completion](https://sec-api.dev/pdufa/plozasiran) | ARWR | Severe Hypertriglyceridemia | completed | "NCT06347016 (Study of Plozasiran in Adults With Severe Hypertriglyceridemia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-17 (ACTUAL); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06347016)) |
| March 2027 | [TRYNGOLZA (olezarsen) primary completion](https://sec-api.dev/pdufa/olezarsen) | IONS | Severe Hypertriglyceridemia | scheduled | "NCT05681351 (CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05681351)) |
| Mar to Jun 2027 | [TRYNGOLZA (olezarsen) topline data readout](https://sec-api.dev/pdufa/olezarsen) | IONS | Severe Hypertriglyceridemia | scheduled | "NCT05681351 (CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05681351)) |
| March 2027 | [Solbinsiran primary completion](https://sec-api.dev/pdufa/solbinsiran) | LLY | Severe Hypertriglyceridemia | scheduled | "NCT07269210 (A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07269210)) |
| Mar to Jun 2027 | [Solbinsiran topline data readout](https://sec-api.dev/pdufa/solbinsiran) | LLY | Severe Hypertriglyceridemia | scheduled | "NCT07269210 (A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07269210)) |
| March 2029 | [REDEMPLO (plozasiran) primary completion](https://sec-api.dev/pdufa/plozasiran) | ARWR | Severe Hypertriglyceridemia | scheduled | "NCT06880770 (Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06880770)) |
| Mar to Jun 2029 | [REDEMPLO (plozasiran) topline data readout](https://sec-api.dev/pdufa/plozasiran) | ARWR | Severe Hypertriglyceridemia | scheduled | "NCT06880770 (Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06880770)) |

## Drugs

- [REDEMPLO (plozasiran)](https://sec-api.dev/pdufa/plozasiran) (ARWR)
- [TRYNGOLZA (olezarsen)](https://sec-api.dev/pdufa/olezarsen) (IONS)
- [Solbinsiran](https://sec-api.dev/pdufa/solbinsiran) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/severe-hypertriglyceridemia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Severe Hypertriglyceridemia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/severe-hypertriglyceridemia

```bibtex
@misc{secapidev_indications_severe_hypertriglyceridemia_20261116,
  title        = {Severe Hypertriglyceridemia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/severe-hypertriglyceridemia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_severe_hypertriglyceridemia_20261116","title":"Severe Hypertriglyceridemia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/severe-hypertriglyceridemia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
